After a strong period of performance, biopharma-focused hedge funds have seen investor enthusiasm moderate. Managers remain optimistic about innovation in the sector, but elevated valuations and changing market conditions are prompting greater selectivity....
Continue Reading
Sign up for FREE to read the full article and access 131K+ alternative investment headlines.